Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares traded down 2.6% during trading on Thursday . The stock traded as low as $10.97 and last traded at $10.99, with a volume of 254,726 shares traded. The stock had previously closed at $11.28.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 6th. Brean Capital reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Monday, June 6th. Finally, Jefferies Group reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Friday, June 10th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $15.92.

The stock has a 50 day moving average of $11.03 and a 200-day moving average of $9.14. The company’s market cap is $474.25 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.07. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The company earned $33.30 million during the quarter, compared to analyst estimates of $32.48 million. The company’s revenue for the quarter was up 50.0% on a year-over-year basis. Equities research analysts predict that Vanda Pharmaceuticals Inc. will post ($0.83) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Vanda Pharmaceuticals stock. Bank of Montreal Can increased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,208,918 shares of the biopharmaceutical company’s stock after buying an additional 228,074 shares during the period. Bank of Montreal Can owned 2.82% of Vanda Pharmaceuticals worth $11,255,000 at the end of the most recent quarter.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.